Last checked at 8 Feb 2024 08:59
LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend
(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News3
AZN Share
Chat
AZN Share
Trades5,852
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,132.00
Bid:
12,132.00
Ask:
12,134.00
Change:
-24.00 (-0.20%)
Spread:
2.00 (0.016%)
Open:
12,092.00
High:
12,134.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Trials show AstraZeneca's Lynparza delaying pancreatic cancer progression
Mon, 03rd Jun 2019 07:46
(Sharecast News) - AstraZeneca announced on Monday that its Lynparza pancreatic cancer drug has returned positive phase three trial results, doubling the amount of patients with no disease progression.Three-year overall survival data showed no disease progression at one year for 34% of patients using Lynparza versus 15% on placebos, while 22% of patients with Lynparza had no progression compared to 15% on placebo after two years in multi-centre trials that saw subjects taking two 300mg doses per day.The FTSE 100-traded company said that Lynparza improved the time without disease progression by a median of 7.4 months compared to 3.8 months with placebo in patients with germline BRCA-mutated metastatic pancreatic cancer.José Baselga, executive vice president of oncology research & development, said: "These unprecedented results raise new hope for patients that have seen little progress over a long period of time. From as early as six months after initiation, more than twice as many patients taking Lynparza lived without progression of their disease compared to those on placebo and we are now working with regulatory authorities to bring Lynparza to patients as quickly as possible."The drug is a first-in-class PARP inhibitor and blocks DNA damage response in cells and tumours harbouring a deficiency in homologous recombination repair, leading to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.The drug is currently approved in over 60 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, and in the US, Canada and Brazil as a maintenance treatment of BRCAm advanced ovarian cancer following response to platinum-based chemotherapyAstraZeneca's shares were down 0.60% at 5,798.00p at 0801 BST.
More News
8 Feb 2024 08:44
TOP NEWS: AstraZeneca confident after 2023 profit more than doubles
(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.
Read more8 Feb 2024 07:58
AstraZeneca shares slip as Q4 profits miss forecasts
(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.
Read more8 Feb 2024 07:50
LONDON BRIEFING: Unilever sets new buyback; Astra profit surges
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.
Read more2 Feb 2024 08:38
AstraZeneca celebrates latest successful trial of acoramidis in Japan
(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.
Read more2 Feb 2024 06:22
TOP NEWS: US sends drugmakers initial offers in Medicare price talks
(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
Read more1 Feb 2024 15:52
UK earnings, trading statements calendar - next 7 days
| Friday 2 February | |
| YouGov PLC | Trading Statement |
| Monday 5 February | |
| Home REIT PLC | Trading Statement |
| Porvair PLC | Full Year Results |
| Trident Royalties PLC | Trading Statement |
| Vodafone Group PLC | Trading Statement |
| Tuesday 6 February | |
| Alumasc Group PLC | Half Year Results |
| BP PLC | Full Year Results |
| Filtronic PLC | Half Year Results |
| Mattioli Woods PLC | Half Year Results |
| Renishaw PLC | Half Year Results |
| Virgin Money UK PLC | Trading Statement |
| Wednesday 7 February | |
| Ashmore Group PLC | Half Year Results |
| Barratt Developments PLC | Half Year Results |
| HydrogenOne Capital Growth PLC | Trading Statement |
| Phoenix Spree Deutschland Ltd | Trading Statement |
| PZ Cussons PLC | Half Year Results |
| Smurfit Kappa Group PLC | Full Year Results |
| UK Commercial Property REIT Ltd | Trading Statement |
| Thursday 8 February | |
| Anglo American PLC | Trading Statement |
| AstraZeneca PLC | Full Year Results |
| British American Tobacco PLC | Full Year Results |
| Compass Group PLC | Trading Statement |
| Redrow PLC | Half Year Results |
| SSE PLC | Trading Statement |
| Unilever PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
29 Jan 2024 08:19
TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US
(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.
Read more22 Jan 2024 11:45
BioNTech challenges AstraZeneca with breast cancer precision drug trial
FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.
Read more19 Jan 2024 09:28
TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH
(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.
Read more16 Jan 2024 17:17
FTSE 100 hits one-month low, precious miners biggest drag
FTSE 100 down 0.5%, FTSE 250 flat
*Read more16 Jan 2024 16:17
London close: Stocks finish lower as wage growth eases
(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.
Read more16 Jan 2024 11:58
LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth
(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.
Read more16 Jan 2024 09:14
LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more16 Jan 2024 08:15
UBS downgrades AstraZeneca to 'sell'
(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.
Read more